Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicaid Gets Higher Rebates For Brand Drugs Compared To Medicare Part D, OIG Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Findings could carry extra significance as congressional "super committee" looks for ways to cut at least $1.2 trillion in federal spending.

You may also be interested in...



OIG Urges Look At Additional Part D Rebates

Congress and CMS should “explore the costs and benefits” of additional Part D rebates, HHS Inspector General says after finding that rebates for selected brands were “substantially higher” for Medicaid than Medicare. But with GOP-controlled Congress, chances of passing mandatory rebates are slim.

OIG Raises Reimbursement Policy Questions For Avastin And Lucentis In Wake Of CATT Findings

Analysis of money spent on the treatments for wet age-related macular degeneration offers an argument for least costly alternative policy as a way of cutting health care spending.

OIG Raises Reimbursement Policy Questions For Avastin And Lucentis In Wake Of CATT Findings

Analysis of money spent on the treatments for wet age-related macular degeneration offers an argument for least costly alternative policy as a way of cutting health care spending.

Related Content

Topics

UsernamePublicRestriction

Register

PS072644

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel